目的 研究吗替麦考酚酸酯(mycophenolate mofetil, MMF)及其活性代谢物麦考酚酸(mycophenolic acid, MPA)的跨膜转运机制。方法 建立Caco-2细胞单层模型, 进行吗替麦考酚酸酯及麦考酚酸转运实验, 用LC-MS/MS方法测定转运实验样品中吗替麦考酚酸酯和麦考酚酸浓度, 计算表观通透系数Papp和外排率Pratio, 评价药物转运及外排作用, P-糖蛋白(P-glycoprotein, P-gp)抑制剂维拉帕米用于评价P-gp在吗替麦考酚酸酯和麦考酚酸肠道吸收转运中的作用。结果 麦考酚酸在10、50和100 μmol·L-1的双向转运的表观通透系数Papp, ab 分别为(9.70±0.40)×106 cm·s-1、(9.35±0.62)×106cm·s-1和(8.69±0.69)×106cm·s-1;外排率Pratio分别为1.39、1.22和1.22, 维拉帕米明显降低了外排率。吗替麦考酚酸酯在穿过Caco-2细胞单层转运过程中大部分被水解为麦考酚酸, 麦考酚酸转运的量随转运时间延长而不断增加, 而吗替麦考酚酸酯转运的量随时间无明显变化。维拉帕米对吗替麦考酚酸酯转运无明显影响。结论 麦考酚酸的跨膜转运受到由转运载体介导的主动转运外排作用影响, P-gp参与了麦考酚酸的跨膜转运。吗替麦考酚酸酯的跨膜转运不存在P-gp的作用, 为被动转运。
Abstract
OBJECTIVE To investigate the mechanism of transmembrane transport of mycophenolate mofetil (MMF) and its active metabolite mycophenolic acid (MPA). METHODS Caco-2 cell monolayer model was developed for MMF and MPA transport experiment, and the LC-MS/MS method was used for the determination of MMF and MPA concentration in transport medium. The apparent permeability coefficient (Papp) and efflux ratio (Pratio) were calculated and used for the evaluation of the ability of drug transport and drug efflux across Caco-2 cell monolayer. RESULTSThe Papp of MPA in two-way transport experiment (Papp, ab and Papp, ba) at 10, 50 and 100 μmol·L-1 were(9.70±0.40)×106 cm·s-1, (9.35±0.62)×106cm·s-1, (8.69±0.69)×106cm·s-1, respectively. Pratiowere 1.39, 1.22 and 1.22, respectively.Pratioof MPA was reduced by verapamil, a well-known P-glycoprotein inhibitor. MMF was mostly hydrolyzed to MPA during the transport process across the Caco-2 cell monolayer. The amount of MPA transported increased with time, but the amount of MMF transported changed not significantly over time and no significant effect of verapamil was observed. CONCLUSION The transmembrane transport of MPA is affected by active transportefflux mediated by transporter with P-gp involved. No effect of P-gp is found in MMF transmembrane transport, which is passive transport.
关键词
吗替麦考酚酸酯 /
麦考酚酸 /
跨膜转运 /
机制 /
P-糖蛋白
{{custom_keyword}} /
Key words
mycophenolate mofetil /
mycophenolic acid /
transmembrane transport /
mechanism /
P-glycoprotein
{{custom_keyword}} /
中图分类号：
R285.5
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
ALLISON A G, EUGUI E M. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection.Transplantation, 2005, 80 (suppl 2):181-190. STAATZ C E, TETT S E. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet, 2007, 46(1):13-58. PAWINSKI T, DURLIK M, SZLASKA I, et al. Comparison of mycophenolic acid pharmacokineticparameters in kidney transplant patients within thefirst 3 months post-transplant. J Clin Pharm Ther, 2006, 31(1): 27-34. VAN HEST R M, MATHOT R A, VULTO A G, et al. Within-patient variability of mycophenolic acid exposure: Therapeutic drug monitoring from a clinical point of view . Ther Drug Monit, 2006, 28(1):31-34. YU Z C, ZHOU P J, XU D, et al. Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patients. Br J Clin Pharmacol, 2006, 62 (4):446-452. MICHEL M, JACQUES M, DJAMILA C E, et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated withmycophenolate mofetil. Clin Chem, 2001;47(1): 88-94. HALE M D, NICHOLLS A J, BULLINGHAM R E, et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renaltransplantation. Clin Pharmacol Ther, 1998, 64(6): 672-683. YU Z C, GAO Y, TIANW W, et al. Development and validation of Caco-2 cell monolayers-model of intestinal transport . Chin J Clin Pharm(中国临床药学杂志), 2012, 21(4): 218-221. YU Z C, JIANG T, QU J Y, et al. Simultaneous determination of mycophenolate mofetil and mycophenolic acid in transport mediumof Caco-2 cellmonolayers by HPLC-MS/MS .Pharm Care Res(药学服务与研究), 2012, 12(6):423-426. ZHOU S, FENG X, KESTELL P, et al. Transport of the investigational anti-cancer drug 5, 6-dimethylxan-thenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells. Eur J Pharm Sci, 2005, 24(5):513-524. CHENG C, BAHADDURI P M, POLLI J E, et al.Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos, 2006, 34(12):1976-1984. WANG Q, STRAB R, KARDOS P, et al.Application and limitation of inhibitors in drug-transporter interactions studies. Int J Pharm, 2008, 356(1-2):12-18. IMAI T, IMOTO M, SAKAMOTO H, et al. Identification of esterases expressed in Caco-2 cells and effects of their hydrolyzing activity in predicting human intestinal absorption. Drug Metab Dispos, 2005, 33(8):1185-1190. WILLIAMS E T, JONES K O, PONSLER G D, et al.The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2.Drug Metab Dispos, 2008, 36(7):1227-1232. IMAI T. Human carboxylesterase isozymes: Catalytic properties and rational drug design. Drug Metab Pharmacokinet, 2006, 21(3):173-185. SHA X Y, FANG X L, WU Y J.The in vitro kinetics of uptake, transport and efflux of 9-nitrocamptothecin in Caco-2 cell model .Acta Pharm Sin(药学学报), 2004, 39(10):839-843. PERLOFF M D, STORMER E, VON MOLTKE L L, et al. Rapid assessment of P-glycoprotein inhibition and induction in vitro. Pharm Res, 2003, 20(8): 1177-1183. LI H, JIN H E, KIM W, et al. Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecanin Caco-2 and MDCKII cells.Pharm Res, 2008, 25(11): 2601-2612. JIAO Z, ZHAN G M, LIANG H Q, et al.Population pharmacokineticsof mycophenolic acid in Chinese adult renaltransplant patients. Chin Pharm J(中国药学杂志), 2007, 42(1): 57-61.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(1162 KB)
